Gary Remington

Summary

Country: Canada

Publications

  1. doi The neurobiology of relapse in schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada Centre for Addiction and Mental Health CAMH, Toronto, Ontario, Canada Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada Campbell Family Mental Health Research Institute, Toronto, Ontario, Canada Electronic address
    Schizophr Res 152:381-90. 2014
  2. doi Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials
    Naren P Rao
    Centre for Addiction and Mental Health CAMH, 250 College Street, Toronto, M5T 1R8, Canada 1 416 535 8501 ext 4864 1 416 979 4292
    Expert Opin Pharmacother 15:373-83. 2014
  3. doi Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?
    Gary Remington
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Psychopharmacology (Berl) 225:505-18. 2013
  4. doi Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia
    Clement C Zai
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Schizophr Res 106:248-52. 2008
  5. doi Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model
    Melanie Dawn Guenette
    Institute of Medical Science, University of Toronto, 1 King s College Circle, Toronto M5S1A8, Canada
    Schizophr Res 146:162-9. 2013
  6. doi Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians
    Renan P Souza
    Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Eur Neuropsychopharmacol 20:688-94. 2010
  7. doi Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia
    Clement C Zai
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Eur Neuropsychopharmacol 19:317-28. 2009
  8. doi Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration
    Araba F Chintoh
    Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 28:494-9. 2008
  9. doi Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia
    Takefumi Suzuki
    Centre for Addiction and Mental Health, Geriatric Mental Health Program and Multimodal Imaging Group, and Department of Psychiatry, University of Toronto, Ontario, Canada, and Keio University School of Medicine, Department of Neuropsychiatry, Tokyo, Japan
    Br J Psychiatry 199:275-80. 2011
  10. pmc Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study
    Hiroyoshi Takeuchi
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Schizophr Bull 39:993-8. 2013

Detail Information

Publications79

  1. doi The neurobiology of relapse in schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada Centre for Addiction and Mental Health CAMH, Toronto, Ontario, Canada Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada Campbell Family Mental Health Research Institute, Toronto, Ontario, Canada Electronic address
    Schizophr Res 152:381-90. 2014
    ..We propose that it is shaped by the form of illness and in place from the outset, modified by constitutional factors like resilience, as well as treatment, and confounded by secondary forms of relapse. ..
  2. doi Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials
    Naren P Rao
    Centre for Addiction and Mental Health CAMH, 250 College Street, Toronto, M5T 1R8, Canada 1 416 535 8501 ext 4864 1 416 979 4292
    Expert Opin Pharmacother 15:373-83. 2014
    ..Dopamine continues to represent a critical line of investigation, although much of the work now focuses on its potential in other symptom domains...
  3. doi Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?
    Gary Remington
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Psychopharmacology (Berl) 225:505-18. 2013
    ..A safety-related threshold has also been proposed, as well as therapeutic lower and upper thresholds. While there has been reasonable consensus regarding a lower therapeutic threshold, this is not the case for the upper thresholds...
  4. doi Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia
    Clement C Zai
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Schizophr Res 106:248-52. 2008
    ..AKT1 polymorphisms and haplotypes were not significantly associated with TD. However, we detected a significant interaction between rs6275 of DRD2 and rs3730358 of AKT1 (p<1 x 10(-5))...
  5. doi Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model
    Melanie Dawn Guenette
    Institute of Medical Science, University of Toronto, 1 King s College Circle, Toronto M5S1A8, Canada
    Schizophr Res 146:162-9. 2013
    ..Results suggest that α1 and 5HT2A receptor antagonism may be involved in glucose dysregulation with AAP treatment, however, the exact mechanisms involved remain unknown...
  6. doi Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians
    Renan P Souza
    Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Eur Neuropsychopharmacol 20:688-94. 2010
    ..These findings should be read with caution particularly before independent replication...
  7. doi Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia
    Clement C Zai
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Eur Neuropsychopharmacol 19:317-28. 2009
    ..007). We also found evidence of interaction between BDNF and DRD3 polymorphisms. Further studies are needed to confirm these findings...
  8. doi Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration
    Araba F Chintoh
    Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 28:494-9. 2008
    ..We present novel findings highlighting an olanzapine-induced deficit in beta-cell functioning...
  9. doi Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia
    Takefumi Suzuki
    Centre for Addiction and Mental Health, Geriatric Mental Health Program and Multimodal Imaging Group, and Department of Psychiatry, University of Toronto, Ontario, Canada, and Keio University School of Medicine, Department of Neuropsychiatry, Tokyo, Japan
    Br J Psychiatry 199:275-80. 2011
    ..Improvements are greatest in the earlier weeks of antipsychotic treatment of patients with non-resistant schizophrenia...
  10. pmc Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study
    Hiroyoshi Takeuchi
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Schizophr Bull 39:993-8. 2013
    ..Moreover, potential risks of relapse following antipsychotic dose reduction should be thoroughly investigated in longer term studies. ..
  11. doi Clozapine's role in the treatment of first-episode schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Canada
    Am J Psychiatry 170:146-51. 2013
    ....
  12. doi Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Canada
    J Clin Psychopharmacol 32:95-9. 2012
    ....
  13. ncbi Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective
    Renan P Souza
    Neurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Hum Psychopharmacol 26:21-7. 2011
    ..Our results suggest that more studies in this context are required to shed light in the molecular mechanisms underlying antipsychotic response and tardive dyskinesia occurrence...
  14. doi Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia
    Renan P Souza
    Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
    Int Clin Psychopharmacol 25:264-9. 2010
    ..None of these results survived correction for multiple testing. Overall, our results do not support a genetic association between tardive dyskinesia and PDE4B...
  15. doi Early prediction of clinical and functional outcome in schizophrenia
    Ofer Agid
    Schizophrenia Program, Center for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Canada
    Eur Neuropsychopharmacol 23:842-51. 2013
    ....
  16. doi Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model
    Margaret Hahn
    Institute of Medical Science, University of Toronto, 1 King s College Circle, Toronto, Canada
    Schizophr Res 131:90-5. 2011
    ....
  17. doi An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis
    Ofer Agid
    Schizophrenia Program, Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario, M5T 1R8, Canada
    J Clin Psychiatry 72:1439-44. 2011
    ..Employing a naturalistic design, we examined response rates over 3 circumscribed antipsychotic trials...
  18. doi Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes
    Clement C Zai
    Neurogenetics Section, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Prog Neuropsychopharmacol Biol Psychiatry 34:50-6. 2010
    ..2000) reported an association between TD and the Manganese superoxide dismutase SOD2 (MnSOD) gene Ala9Val (rs4880) polymorphism in a Japanese sample, but most research groups failed to replicate their positive findings...
  19. doi Clozapine and global cognition in schizophrenia
    Tarek K Rajji
    Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, Toronto, Canada
    J Clin Psychopharmacol 30:431-6. 2010
    ..The relative effect and exposure to CLZ and its major metabolite-N-desmethylclozapine (NDMC)-could explain these discrepancies...
  20. ncbi Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia
    Hiroyuki Uchida
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    J Clin Psychiatry 69:1281-6. 2008
    ..The objective of this positron emission tomography (PET) study was to examine the striatal dopamine D(2) binding of long-acting risperidone administered intramuscularly once a month...
  21. ncbi Early use of clozapine for poorly responding first-episode psychosis
    Ofer Agid
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 27:369-73. 2007
    ..The present findings suggest that clozapine may have an important role in the early treatment of first-episode patients whose psychosis does not remit with other second-generation antipsychotics during the first months of treatment...
  22. doi The catechol-O-methyl-transferase gene in tardive dyskinesia
    Clement C Zai
    Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    World J Biol Psychiatry 11:803-12. 2010
    ..Changes in dopamine neurotransmission have been implicated in the etiology of TD, and catechol-O-methyl-transferase (COMT) is an enzyme that metabolizes dopamine...
  23. ncbi A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone
    Gary Remington
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ont M5T 1R8, Canada
    Am J Psychiatry 163:396-401. 2006
    ..The present study used positron emission tomography (PET) to evaluate its dopamine D(2) binding profile at doses of 25, 50, or 75 mg administered every 2 weeks...
  24. doi Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition
    Steve Mann
    Schizophrenia Program, Centre for Addiction and Mental Health CAMH, Toronto, Canada
    Pharmacol Biochem Behav 103:717-22. 2013
    ..We conclude that the rodent model is tenable in evaluating the effects of antipsychotics on weight/body composition...
  25. doi "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial
    Gary Remington
    Schizophrenia Program, Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario M5T 1R8, Canada
    J Clin Psychiatry 72:1042-8. 2011
    ..Based on a better understanding of the brain kinetics of antipsychotics, we have proposed a variation of this approach, "extended" dosing, which allows for intermittent but regular dosing...
  26. ncbi Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data
    Hiroyoshi Takeuchi
    Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan Schizophrenia Division, Complex Mental Illness Program, Centre for Addiction and Mental Health, Toronto, ON, Canada Department of Psychiatry, University of Toronto, ON, Canada Electronic address
    Schizophr Res 150:373-9. 2013
    ....
  27. doi Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching
    Ofer Agid
    Centre for Addiction and Mental Health, Ontario, Canada Department of Psychiatry, University of Toronto, Ontario, Canada
    Eur Neuropsychopharmacol 23:1017-22. 2013
    ..It remains to be established whether further antipsychotic trials are associated with even greater decrements in rate of response. Findings underscore the importance of moving to clozapine when treatment resistance has been established. ..
  28. ncbi Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, Canada M5T 1R8 Institute of Medical Science, University of Toronto, Toronto, ON, Canada Electronic address
    J Psychiatr Res 47:1590-6. 2013
    ..Here, we use a translational paradigm to measure incentive motivation in individuals with schizophrenia...
  29. ncbi Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients
    Clement C Zai
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Int J Neuropsychopharmacol 10:639-51. 2007
    ..047). Taken together, the present study suggests that DRD2 may be involved in TD in the Caucasian population, although further studies are warranted...
  30. ncbi Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model
    Araba F Chintoh
    Institute of Medical Science, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada
    Schizophr Res 108:127-33. 2009
    ..Our data also support the preclinical use of these clamp procedures in screening putative antipsychotics...
  31. doi Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters
    Margaret K Hahn
    Center for Addiction and Mental Health, Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
    Clin Schizophr Relat Psychoses 6:186-96. 2013
    ....
  32. doi Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia
    Gabriela Novak
    Neuroscience Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Psychiatr Genet 20:39-43. 2010
    ..Although the results of this study are limited by a small sample size, it presents important pilot data and warrants further investigation of the involvement of NR4A1 variants in TD...
  33. ncbi Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia
    Clement C Zai
    Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON, Canada
    J Psychiatr Res 47:1760-5. 2013
    ..001), supporting the dopamine hypothesis of TD. Pending further replication, VMAT2 may be considered a therapeutic target for the treatment and/or prevention of TD...
  34. doi Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model
    Margaret K Hahn
    Center for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8 Institute of Medical Sciences, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada M5S 1A8 Electronic address
    Eur Neuropsychopharmacol 24:448-58. 2014
    ..002). In conclusion, we demonstrate novel findings that at least part of the effect of olanzapine on beta-cell function in vivo is central...
  35. doi Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study
    Sanjeev Sockalingam
    University Health Network, Toronto General Hospital 8EN 225, 200 Elizabeth St, Toronto, Ontario M5G 2C4, Canada
    J Clin Psychiatry 70:1114-9. 2009
    ..Previous open-label studies suggest that sublingual ipratropium bromide may be effective in treating CIH...
  36. doi Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO
    Romina Mizrahi
    PET Centre, Centre for Addiction and Mental Health, Toronto, Canada
    Schizophr Res 131:63-8. 2011
    ..11)C]-(+)-PHNO offer new opportunities for exploring the potential therapeutic significance of the D(3) receptor in schizophrenia and the action of antipsychotics...
  37. doi Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia
    Renan P Souza
    Neurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Psychopharmacology (Berl) 210:347-54. 2010
    ..Clinical trials have also investigated whether GDNF may ameliorate Parkinson's disease symptoms...
  38. pmc Antipsychotic dosing: how much but also how often?
    Gary Remington
    Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Schizophr Bull 36:900-3. 2010
    ..Does this mean we need to (or should) administer antipsychotics at least daily? There is a body of evidence challenging this long-established clinical axiom...
  39. doi Increased stress-induced dopamine release in psychosis
    Romina Mizrahi
    Positron Emission Tomography Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada
    Biol Psychiatry 71:561-7. 2012
    ..However, there is no direct evidence that brain dopaminergic response to stress is exaggerated in psychosis...
  40. doi Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment?
    Lai Fong Chan
    Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Pharmacogenomics 14:1273-81. 2013
    ..This study explored the role of self-reported ethnicity and genetic ancestry on antipsychotic (AP)-induced weight gain and tardive dyskinesia (TD) in schizophrenia...
  41. ncbi A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone
    David Mamo
    Department of Psychiatry, University of Toronto, Montreal, Canada
    Am J Psychiatry 161:818-25. 2004
    ..The affinity of ziprasidone for these receptors in vivo in patients was examined in a positron emission tomography (PET) study...
  42. ncbi Happiness in first-episode schizophrenia
    Ofer Agid
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Canada
    Schizophr Res 141:98-103. 2012
    ..The present study set out to specifically assess happiness in schizophrenia in relation to both clinical and functional measures of outcome...
  43. doi Determining rates of hepatitis C in a clozapine treated cohort
    Sanjeev Sockalingam
    Psychiatry, Health and Disease Division, University Health Network, Toronto, Ontario, Canada
    Schizophr Res 124:86-90. 2010
    ..To determine the prevalence rates of hepatitis C in patients with schizophrenia and schizoaffective disorder being treated with clozapine...
  44. doi Antipsychotics, dopamine D₂ receptor occupancy and clinical improvement in schizophrenia: a meta-analysis
    Zeynep Yilmaz
    Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
    Schizophr Res 140:214-20. 2012
    ..The main objective of this meta-analysis was to analyze the relationship between in vivo estimation of typical and atypical antipsychotic D₂ receptor occupancy and treatment response in SCZ...
  45. ncbi The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Canada
    Schizophr Res 90:229-37. 2007
    ..More sophisticated measurement tools such as MEMS may assist us in better understanding how level and pattern of antipsychotic noncompliance, factors that at present remain poorly understood, impact on symptom exacerbation...
  46. doi Treatment resistant schizophrenia and response to antipsychotics: a review
    Takefumi Suzuki
    Centre for Addiction and Mental Health, Geriatric Mental Health Program, Toronto, Ontario, Canada
    Schizophr Res 133:54-62. 2011
    ..There remains a lack of agreement regarding criteria for treatment-resistant schizophrenia (TRS) and definition of response...
  47. doi Progress in defining optimal treatment outcome in schizophrenia
    Gary Remington
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    CNS Drugs 24:9-20. 2010
    ..To this end, the field has now embraced a recovery model that is seen as a process, multidimensional and individualized, rather than dichotomous and symptom driven...
  48. doi Insulin resistance following continuous, chronic olanzapine treatment: an animal model
    Araba F Chintoh
    Institute of Medical Science, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada M5S 1A8
    Schizophr Res 104:23-30. 2008
    ..However, chronic treatment with olanzapine was found to confer both hepatic and peripheral insulin resistance independent of weight gain, indicating a direct effect on glucose dysregulation...
  49. doi Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention
    Ofer Agid
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    Expert Opin Pharmacother 11:2301-17. 2010
    ..However, nonadherence with antipsychotic treatment is a significant issue, with estimates as high as 90%...
  50. doi Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia
    Monica Hazra
    Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada
    Psychiatry Clin Neurosci 65:676-8. 2011
    ..A three-fold decrease in the prevalence of antipsychotic polypharmacy was observed between 2006 (18.3%) and 2008 (6.6%). Thus, active monitoring of prescriptions with educational interventions could reduce antipsychotic polypharmacy...
  51. ncbi Augmentation strategies in clozapine-resistant schizophrenia
    Gary Remington
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    CNS Drugs 19:843-72. 2005
    ..A priori, an endpoint needs to be established and the trial discontinued unless results firmly support added benefits...
  52. doi Lack of association of NALCN genetic variants with schizophrenia
    Renan P Souza
    Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Psychiatry Res 185:450-2. 2011
    ..We analyzed 21 polymorphisms in 464 schizophrenia subjects, 220 controls subjects and 119 small nuclear families. We observed nominal association with rs9518320 and rs9518331, suggesting that NALCN is not related to schizophrenia risk...
  53. ncbi A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder
    Hiroyoshi Takeuchi
    Schizophrenia Division Complex Mental Illness Program, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, M5T 1R8, Canada
    Psychopharmacology (Berl) 228:175-85. 2013
    ..Numerous case reports have suggested that aripiprazole can worsen psychotic symptoms in schizophrenia...
  54. doi Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials
    Naren P Rao
    Centre for Addiction and Mental Health CAMH, 250 College Street, Toronto, M5T 1R8, Canada
    Expert Opin Investig Drugs 22:881-94. 2013
    ..The present article reviews the scientific rationale for dopaminergic medications historically and the shift in our thinking since, which is clearly reflected in the investigational drugs detailed...
  55. doi Neuroimaging evidence for the deficit subtype of schizophrenia
    Aristotle N Voineskos
    Department of Psychiatry, Centre for Addiction and Mental Health, Toronto, Canada
    JAMA Psychiatry 70:472-80. 2013
    ..Dividing schizophrenia into "deficit" and "nondeficit" subtypes may reduce heterogeneity and facilitate identification of neurobiological markers of disease...
  56. doi Genetics of antipsychotic-induced side effects and agranulocytosis
    Nabilah I Chowdhury
    Neurogenetics Section, Neuroscience Department, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T1R8, Canada
    Curr Psychiatry Rep 13:156-65. 2011
    ..However, efforts to identify key gene mechanisms that will be useful in predicting antipsychotic side effects in the clinical setting have not been fully successful, and further studies with larger sample sizes are required...
  57. pmc Interventions to reduce weight gain in schizophrenia
    Guy Faulkner
    Faculty of Physical Education and Health, University of Toronto, Toronto, Canada
    Schizophr Bull 33:654-6. 2007
  58. ncbi Where to position clozapine: re-examining the evidence
    Ofer Agid
    Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario
    Can J Psychiatry 55:677-84. 2010
    ..To review clozapine's position in treatment algorithms for schizophrenia...
  59. ncbi Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making
    George Foussias
    Schizophrenia Program, Centre for Addiction and Mental Health, Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario
    Can J Psychiatry 55:117-25. 2010
    ....
  60. ncbi Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood
    Huma Saeedi
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Schizophr Res 85:222-31. 2006
    ..The present results suggest that DA D(2) blockade, as induced by haloperidol, produces important deficits that extend beyond motor or endocrine changes...
  61. doi Exploring the neural correlates of delusions of reference
    Mahesh Menon
    Department of Psychiatry, University of Toronto, Toronto, Canada
    Biol Psychiatry 70:1127-33. 2011
    ..The cortical midline structures (CMS) and subcortical regions, including the amygdala and striatum, are linked with self-reference in healthy adults. Less is known about the neural substrates of altered self-reference in schizophrenia...
  62. doi Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment
    Gary Remington
    University of Toronto, Toronto, Ontario, Canada
    Expert Rev Neurother 11:589-607. 2011
    ..This shift in thinking has important theoretical implications from the standpoint of etiology and pathophysiology, but also clinically in terms of treatment and drug development...
  63. doi Methamphetamine use and schizophrenia: a population-based cohort study in California
    Russell C Callaghan
    Centre for Addiction and Mental Health, Toronto
    Am J Psychiatry 169:389-96. 2012
    ..This possibility is discounted in the Western literature. To investigate the relationship between drug use and later schizophrenia, the authors conducted a large-scale cohort study of drug users initially free of persistent psychosis...
  64. doi Alterations of dopamine and serotonin transmission in schizophrenia
    Gary Remington
    Department of Psychiatry, Faculty of Medicine, University of Toronto, Ontario, Canada
    Prog Brain Res 172:117-40. 2008
    ..At present, there is particular interest in the 5-HT(1A), 5-HT(2C), 5-HT(6) and 5-HT(7) receptors as the search for improved pharmacological treatments for schizophrenia continues...
  65. ncbi Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats
    Peter Turrone
    Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
    Biol Psychiatry 57:406-11. 2005
    ..The objective of this study was to determine whether continuous, versus intermittent, olanzapine (OLZ) infusion differently affects the development of VCMs...
  66. ncbi Body mass index, waist circumference and quality of life in individuals with schizophrenia
    Guy Faulkner
    Faculty of Physical Education and Health, University of Toronto, Ontario, Canada M5S 2W6
    Schizophr Res 90:174-8. 2007
    ..The primary objective was to examine the differential relationship between waist circumference, body mass index, and self-reported quality of life in patients with schizophrenia...
  67. doi Attribution style as a factor in psychosis and symptom resolution
    Romina Mizrahi
    CAMH, PET Centre, Toronto, Ontario, Canada
    Schizophr Res 104:220-7. 2008
    ....
  68. doi Management of schizophrenia in late life with antipsychotic medications: a qualitative review
    Takefumi Suzuki
    Centre for Addiction and Mental Health, Geriatric Mental Health Program, Toronto, ON, Canada
    Drugs Aging 28:961-80. 2011
    ..However, data on geriatric patients with schizophrenia are generally scarce, particularly for treatment-resistant subpopulations, underscoring the need for more research in this important area...
  69. doi Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study
    Gagan Fervaha
    Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada Institute of Medical Science, University of Toronto, Toronto, Canada Electronic address
    Schizophr Res 151:203-8. 2013
    ..The present study sought to focus on global life satisfaction as a key subjective domain and determine its relationship with clinical variables...
  70. ncbi Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects
    Margaret K Hahn
    Center for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada
    J Clin Psychopharmacol 30:706-10. 2010
    ..These findings support topiramate as a viable augmentation strategy in clozapine partial responders, with evidence of both clinical and metabolic benefits...
  71. ncbi Emerging drugs for schizophrenia
    Ofer Agid
    Centre for Addiction and Mental Health, Schizophrenia Program, Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Expert Opin Emerg Drugs 13:479-95. 2008
    ..As the dust settles on this period and substantial data, as well as practical prescribing experience, are available, we examine what has been gained and what can be learned...
  72. pmc Negative symptoms in schizophrenia: avolition and Occam's razor
    George Foussias
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Schizophr Bull 36:359-69. 2010
    ..Further exploration and clarification of this core deficit will ultimately enhance our neurobiological understanding of schizophrenia, as well as strategies that may improve outcome...
  73. doi Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study
    Wenzie Ng
    Centre for Addiction and Mental Health, Geriatric Mental Health Program, Toronto, Ontario M5T 1R8, Canada
    Ther Drug Monit 31:360-6. 2009
    ..These findings may account for some of the variability in clozapine exposure and have important implications for individualized drug dosing and therapeutic drug monitoring...
  74. ncbi Rational pharmacotherapy in early psychosis
    Gary Remington
    Medical Assessment Program for Schizophrenia, Centre for Addiction and Mental Health, 250 College Street, Totonto, Ontario M5T 1R8, Canada
    Br J Psychiatry Suppl 48:s77-84. 2005
    ..An increased focus in research specific to first-episode schizophrenia has provided a rapidly growing body of evidence that can be directly translated to clinical practice...
  75. ncbi Validation of a physical activity assessment tool for individuals with schizophrenia
    Guy Faulkner
    Faculty of Physical Education and Health, University of Toronto, 55 Harbord Street, Toronto, Ontario, Canada M5S 2W6
    Schizophr Res 82:225-31. 2006
    ..The objective of this study was to provide preliminary validation of the Short-Form International Physical Activity Questionnaire (IPAQ), a measurement tool that could prove useful for both clinicians and researchers in the field...
  76. ncbi Tardive dyskinesia: eliminated, forgotten, or overshadowed?
    Gary Remington
    Faculty of Medicine, University of Toronto, Ontario, Canada
    Curr Opin Psychiatry 20:131-7. 2007
    ..The present review focuses on atypical antipsychotics and tardive dyskinesia...
  77. ncbi Predictors and markers of clozapine response
    Carmen Chung
    Centre for Addiction and Mental Health, Schizophrenia Program, 250 College Street, Toronto, Ontario, M5T 1R8, Canada
    Psychopharmacology (Berl) 179:317-35. 2005
    ..With other atypical antipsychotics now available, having predictors of clozapine response would be of considerable value, offering clinicians guidance in their decision as to when, and if, a trial of clozapine is warranted...
  78. ncbi The use of pharmacotherapy in the prodrome of schizophrenia
    Gary Remington
    Department of Psychiatry, University of Toronto, Toronto, Canada
    CNS Spectr 9:579-86. 2004
    ..We now have a limited number of published reports addressing this topic and these are reviewed here...
  79. ncbi Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness
    Valerie H Taylor
    Women s College Hospital, Toronto, Ontario
    Can J Psychiatry 57:5-12. 2012
    ..Our review examines issues associated with common chronic mental illnesses that may underlie this association and warrant further study if we hope to clinically intervene to control this life-threatening comorbidity...